Latest Regulatory News

Pharmaceutical manufacturer ANO has been hit with a US FDA Import Alert, joining several Australian peers amid wider regulatory tensions. The company is mobilising expert consultants and preparing a petition to lift the alert within weeks.

Skylark Minerals Limited has applied for ASX quotation of 37.98 million fully paid ordinary shares from a previously approved placement, signalling a key step in its capital expansion strategy.

Mesoblast Limited reports a 60% jump in Ryoncil sales for the December quarter, underpinned by a new $125 million financing facility that strengthens its balance sheet and strategic flexibility.

QGold Pty Ltd has raised its takeover offer for Venus Metals Corporation shares to $0.21 and extended the offer period to 30 January 2026, signalling a firm final bid in the ongoing acquisition attempt.

Energy Transition Minerals (ETM) has appointed Ballard Partners as strategic advisors in the US, reinforcing its plan to list on the Nasdaq Stock Exchange and deepen its engagement with American stakeholders.

InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.

Rio Tinto and Glencore have entered preliminary talks about a possible all-share merger via a Court-sanctioned scheme of arrangement, though no firm offer has been made. The mining giants have until early February to decide on progressing the deal.

Lunnon Metals has reported significant gold intercepts at its Paringa West prospect, confirming a promising new geological structure within the prolific St Ives gold camp. The results bolster the company’s exploration ambitions in Western Australia’s renowned Foster-Baker Project.

Eastern Metals Limited will have its trading suspension lifted on 9 January 2026, marking its return to the ASX after meeting key listing requirements.

Ryzon Materials Limited faces ASX scrutiny over the timing and disclosure of a $1 million advance from Xinhai Mining, with the company responding to regulatory queries and committing to improved governance.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

RocketBoots Limited has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to an administrative oversight during a holdings restructure. The company affirms its compliance policies and has taken steps to prevent future delays.